Switch theme
Sign up to access all valuation multiples
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
2017
268
LTM Revenue $767M
LTM EBITDA $263M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harmony Biosciences Hldgs has a last 12-month revenue (LTM) of $767M and a last 12-month EBITDA of $263M.
In the most recent fiscal year, Harmony Biosciences Hldgs achieved revenue of $715M and an EBITDA of $233M.
Harmony Biosciences Hldgs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harmony Biosciences Hldgs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $767M | XXX | $715M | XXX | XXX | XXX |
| Gross Profit | $599M | XXX | $558M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $263M | XXX | $233M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $218M | XXX | $191M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $165M | XXX | $145M | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Harmony Biosciences Hldgs's stock price is $34.
Harmony Biosciences Hldgs has current market cap of $2.0B, and EV of $1.6B.
See Harmony Biosciences Hldgs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $2.0B | XXX | XXX | XXX | XXX | $2.77 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Harmony Biosciences Hldgs has market cap of $2.0B and EV of $1.6B.
Harmony Biosciences Hldgs's trades at 2.3x EV/Revenue multiple, and 7.1x EV/EBITDA.
Equity research analysts estimate Harmony Biosciences Hldgs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harmony Biosciences Hldgs has a P/E ratio of 12.0x.
See valuation multiples for Harmony Biosciences Hldgs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBIT | 7.6x | XXX | 8.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.0x | XXX | 13.6x | XXX | XXX | XXX |
| EV/FCF | 7.2x | XXX | 7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHarmony Biosciences Hldgs's last 12 month revenue growth is 18%
Harmony Biosciences Hldgs's revenue per employee in the last FY averaged $2.7M, while opex per employee averaged $1.4M for the same period.
Harmony Biosciences Hldgs's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harmony Biosciences Hldgs's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Harmony Biosciences Hldgs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 56% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harmony Biosciences Hldgs acquired XXX companies to date.
Last acquisition by Harmony Biosciences Hldgs was XXXXXXXX, XXXXX XXXXX XXXXXX . Harmony Biosciences Hldgs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Harmony Biosciences Hldgs founded? | Harmony Biosciences Hldgs was founded in 2017. |
| Where is Harmony Biosciences Hldgs headquartered? | Harmony Biosciences Hldgs is headquartered in United States of America. |
| How many employees does Harmony Biosciences Hldgs have? | As of today, Harmony Biosciences Hldgs has 268 employees. |
| Who is the CEO of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's CEO is Dr. Jeffrey M. Dayno, M.D.. |
| Is Harmony Biosciences Hldgs publicy listed? | Yes, Harmony Biosciences Hldgs is a public company listed on NAS. |
| What is the stock symbol of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs trades under HRMY ticker. |
| When did Harmony Biosciences Hldgs go public? | Harmony Biosciences Hldgs went public in 2020. |
| Who are competitors of Harmony Biosciences Hldgs? | Similar companies to Harmony Biosciences Hldgs include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's current market cap is $2.0B |
| What is the current revenue of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's last 12 months revenue is $767M. |
| What is the current revenue growth of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Harmony Biosciences Hldgs? | Current revenue multiple of Harmony Biosciences Hldgs is 2.1x. |
| Is Harmony Biosciences Hldgs profitable? | Yes, Harmony Biosciences Hldgs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's last 12 months EBITDA is $263M. |
| What is Harmony Biosciences Hldgs's EBITDA margin? | Harmony Biosciences Hldgs's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Harmony Biosciences Hldgs? | Current EBITDA multiple of Harmony Biosciences Hldgs is 6.3x. |
| What is the current FCF of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's last 12 months FCF is $228M. |
| What is Harmony Biosciences Hldgs's FCF margin? | Harmony Biosciences Hldgs's last 12 months FCF margin is 30%. |
| What is the current EV/FCF multiple of Harmony Biosciences Hldgs? | Current FCF multiple of Harmony Biosciences Hldgs is 7.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
